Entact Bio
Entact Bio is a biotechnology company focused on developing a new class of medicines called ENTACs that enhance the function of beneficial proteins. Their mission is to expand the universe of treatable diseases by leveraging the natural ability of deubiquitinases (DUBs) to regulate and enhance protein function, creating innovative therapeutics for patients in need.
Industries
Nr. of Employees
small (1-50)
Entact Bio
Watertown, Massachusetts, United States, North America
Products
Orally bioavailable heterobifunctional small molecules for targeted protein enhancement
Drug candidates designed as bifunctional small molecules that bring a target protein into proximity with deubiquitylase enzymes to remove ubiquitin and thereby increase protein stability, alter localization, or modify activity.
Orally bioavailable heterobifunctional small molecules for targeted protein enhancement
Drug candidates designed as bifunctional small molecules that bring a target protein into proximity with deubiquitylase enzymes to remove ubiquitin and thereby increase protein stability, alter localization, or modify activity.
Services
End-to-end discovery platform for targeted protein enhancement
Integrated internal platform supporting target identification, hypothesis validation, design and optimization of heterobifunctional small molecules that recruit deubiquitinases to modulate target proteins.
End-to-end discovery platform for targeted protein enhancement
Integrated internal platform supporting target identification, hypothesis validation, design and optimization of heterobifunctional small molecules that recruit deubiquitinases to modulate target proteins.
Expertise Areas
- Targeted protein enhancement / induced-proximity therapeutics
- Deubiquitylase (DUB) biology and ubiquitin signaling
- Small-molecule medicinal chemistry and heterobifunctional design
- Proteomics and mass-spectrometry-based analysis
Key Technologies
- Heterobifunctional small-molecule (induced-proximity) design
- Deubiquitinase recruitment strategies
- Mass spectrometry-based proteomics
- Structure-based drug design (docking, pharmacophores)